Bettina Stubinski

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Daniel D. Mikol, Frederik Barkhof, Peter Chang et al. · The Lancet Neurology · 2008 · 480 citations

Autoimmune Disease, Disease Progression, Neurological Disorder +8

Scoring treatment response in patients with relapsing multiple sclerosis

Jordi Río, Mar Tintoré, Alessio Signori et al. · Multiple Sclerosis Journal · 2012 · 255 citations

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS

Ludwig Kappos, Anthony Traboulsee, Cris S. Constantinescu et al. · Neurology · 2006 · 255 citations

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

Nicola De Stefano, Mark S. Freedman, Frederik Barkhof et al. · The Lancet Neurology · 2011 · 212 citations

Neurological Disorder, Clinical Neurology, Neurology +5

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis

Maria Pia Sormani, D. K. Li, Paolo Bruzzi et al. · Neurology · 2011 · 98 citations